Department of Health Care Policy, Harvard Medical School, Boston (Huskamp, Normand, Mehrotra, Busch); RAND, Arlington, Virginia (Uscher-Pines); U.S. Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles (Raja); Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston (Normand); Division of General Internal Medicine, Beth Israel Deaconess Medical Center, Boston (Mehrotra); McLean Hospital, Belmont, Massachusetts (Busch).
Psychiatr Serv. 2024 Jul 1;75(7):630-637. doi: 10.1176/appi.ps.20230421. Epub 2024 Jan 19.
The authors sought to examine trends in stimulant initiation and follow-up care for attention-deficit hyperactivity disorder (ADHD) via telemedicine.
This retrospective longitudinal study used national, deidentified commercial health insurance outpatient claims among children (ages 2-17 years; N=535,629) and adults (ages 18-64 years; N=2,116,160) from January 2019 through April 2022. Regression analyses were used to examine risk for stimulant initiation, whether initiation occurred via telemedicine or in-person care, and receipt of a follow-up visit.
The mean monthly adjusted number of stimulant initiations per 100,000 enrollees was similar for children before and during the COVID-19 pandemic (prepandemic, 57 initiations; during pandemic, 56 initiations) but increased for adults (prepandemic, 27 initiations; during pandemic, 33 initiations). Initiations via telemedicine peaked at 53%-57% in April 2020 and dropped to about 14% among children and 28% among adults in April 2022. Telemedicine initiations were significantly more common among psychiatrists than among other prescribers (OR=3.70, 95% CI=3.38-4.06 [children]; OR=3.02, 95% CI=2.87-3.17 [adults]) and less common for rural residents (OR=0.57, 95% CI=0.40-0.82 [children]; OR=0.75, 95% CI=0.61-0.92 [adults]). Follow-up care was significantly more common among individuals whose care was initiated via telemedicine than among those receiving in-person care (OR=1.09, 95% CI=1.00-1.19 [children]; OR=1.61, 95% CI=1.53-1.69 [adults]).
Many stimulant treatments were initiated via telemedicine. Proposed rules to prohibit controlled substance prescribing without an in-person evaluation would require significant changes in current practice, potentially limiting access to stimulant medications for ADHD.
作者试图通过远程医疗来研究注意力缺陷多动障碍(ADHD)的兴奋剂起始和后续治疗趋势。
这项回顾性纵向研究使用了全国范围内、未经身份识别的商业健康保险门诊理赔数据,涵盖了 2019 年 1 月至 2022 年 4 月期间的儿童(2-17 岁;n=535629)和成人(18-64 岁;n=2116160)。回归分析用于检查兴奋剂起始的风险,起始是通过远程医疗还是面对面治疗,以及是否接受了随访。
在儿童中,每月每 100000 名参保人调整后的兴奋剂起始人数在新冠大流行之前和期间相似(大流行前为 57 例;大流行期间为 56 例),但在成人中有所增加(大流行前为 27 例;大流行期间为 33 例)。远程医疗起始在 2020 年 4 月达到 53%-57%的峰值,到 2022 年 4 月,儿童的起始比例降至 14%左右,成人的起始比例降至 28%左右。与其他开处方者相比,精神科医生进行远程医疗起始的比例明显更高(OR=3.70,95%CI=3.38-4.06[儿童];OR=3.02,95%CI=2.87-3.17[成人]),农村居民的起始比例较低(OR=0.57,95%CI=0.40-0.82[儿童];OR=0.75,95%CI=0.61-0.92[成人])。与接受面对面治疗的患者相比,通过远程医疗开始治疗的患者接受后续治疗的比例显著更高(OR=1.09,95%CI=1.00-1.19[儿童];OR=1.61,95%CI=1.53-1.69[成人])。
许多兴奋剂治疗是通过远程医疗开始的。拟议的禁止未经面对面评估而开具受控物质处方的规定将要求对现行做法进行重大改变,这可能会限制 ADHD 患者获得兴奋剂药物的机会。